RecruitingNCT05809986

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Sponsor

Novartis Pharmaceuticals

Enrollment

174 participants

Start Date

Nov 27, 2023

Study Type

OBSERVATIONAL

Conditions

Relapsing Multiple Sclerosis

Summary

This non-interventional study will compare the effect of Ofatumumab treatment between patients that began Ofatumumab within the 3 years after Multiple Sclerosis diagnosis and patients that began Ofatumumab with more than 3 years of Multiple Sclerosis diagnosis in a real-world setting in Portugal.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This is an observational study (no new treatment involved) tracking how well ofatumumab (brand name Kesimpta), a self-injectable MS medication, works in real-world Portuguese patients with relapsing multiple sclerosis. **You may be eligible if...** - You are 18 or older and have been diagnosed with relapsing multiple sclerosis (RMS) per 2017 McDonald criteria - You have already started ofatumumab as prescribed by your doctor in Portugal - You are willing and able to complete questionnaires and study assessments **You may NOT be eligible if...** - You have a non-relapsing form of MS (e.g., primary progressive MS) - You have not started ofatumumab treatment - You are not able to provide informed consent or complete assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEROfatumumab

There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis